Apellis Pharmaceuticals Inc Asset Resilience Ratio
Apellis Pharmaceuticals Inc asset resilience ratio. Apellis Pharmaceuticals Inc (APLS) has an Asset Resilience Ratio of 0.58% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Apellis Pharmaceuticals Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Apellis Pharmaceuticals Inc (2020–2024)
Asset resilience ratio of Apellis Pharmaceuticals Inc from 2020 to 2024. This chart shows how Apellis Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read Apellis Pharmaceuticals Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Apellis Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Apellis Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.75 Million | 0.58% |
| Total Liquid Assets | $4.75 Million | 0.58% |
Asset Resilience Insights
- Limited Liquidity: Apellis Pharmaceuticals Inc maintains only 0.58% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Apellis Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Apellis Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Apellis Pharmaceuticals Inc Asset Resilience Ratio by Year (2020–2024)
Apellis Pharmaceuticals Inc asset resilience ratio by year from 2020 to 2024. The table below shows the annual Asset Resilience Ratio data for Apellis Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.55% | $4.85 Million | $885.05 Million | +0.41pp |
| 2023-12-31 | 0.14% | $1.11 Million | $788.73 Million | -0.71pp |
| 2022-12-31 | 0.86% | $6.50 Million | $760.22 Million | -6.07pp |
| 2021-12-31 | 6.92% | $61.03 Million | $881.76 Million | -25.55pp |
| 2020-12-31 | 32.47% | $311.87 Million | $960.57 Million | -- |
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy… Read more